All Modules

Integrating Tyrosine Kinase Inhibitors in Colorectal Cancer Treatment Algorithms: Considerations for NTRK Gene Fusion Targeted Therapy CME Credits: 0.5
In human cancers, gene fusions involving neurotrophic tyrosine receptor kinases (NTRKs) are known drivers of a wide variety of adult and pediatric solid tumors. They are most frequently observed in rare tumors and are rare in more common tumor types.
Faculty: Nilofer Azad, MD, and Christopher Jakubowski, MD Expires: 1/22/2021

Checkpoint Inhibitors for Treatment of Advanced or Metastatic Melanoma: Keeping up with Clinical Advances CME Credits: 0.5
Recent advances in the understanding of the immunology and molecular biology of melanoma have changed the therapeutic landscape for patients with advanced or metastatic melanoma (MM).
Faculty: Richard W. Joseph, MD Expires: 11/14/2019

Optimizing the Use of Targeted Therapies in First and Subsequent Lines of Treatment for ALK-Positive Non-Small Cell Lung Cancer CME Credits: 0.5
Although non-small cell lung cancer (NSCLC) is a lung cancer subtype that comprises up to 90% of patients diagnosed with cancer, it continues to be a leading cause of cancer death.
Faculty: Stefanie Houseknecht, PharmD, BCOP, and Kristen A. Marrone, MD Expires: 04/017/2020

New and Emerging Targeted Therapy Options for Treating Metastatic Renal Cell Carcinoma CME Credits: 0.5
Metastatic renal cell carcinoma (mRCC) has long been associated with a dismal prognosis, but the use of newer targeted small-molecule tyrosine kinase inhibitors (TKIs), immunotherapies, angiogenic monoclonal antibodies (mAbs), and mammalian target of rapamycin (mTOR) inhibitors has improved both progression-free and overall survival for these patients.
Faculty: Fernando J. Kim, MD, MBA, FACS, and Jane Mattei, MD, PhD Expires: 12/03/2020

Emerging Options for Treating Small Cell Lung Cancer: The Potential Role of Immune Checkpoint Inhibitors CME Credits: 0.5
Small cell lung cancer (SCLC) is an aggressive malignancy that grows and disseminates rapidly. Although patients with metastatic SCLC respond well to conventional cancer treatments like platinum-based chemotherapy and radiation, most patients relapse within 1 year and have few therapeutic options.
Faculty: David S. Ettinger, MD Expires: 03/26/2020

Addressing Unmet Needs in Mesothelioma:
Evaluating the Role of Angiokinase Inhibitors
CME Credits: 0.5
Malignant pleural mesothelioma (MPM) is a relatively rare but serious malignancy that arises from the mesothelial surfaces of the pleural cavity. Most cases of MPM are associated with workplace exposure to high levels of asbestos, with the onset of cancer typically occurring 20 to 50 years after asbestos exposure.
Faculty: Patrick Forde, MBBCh Expires: 3/5/2019

CINV Prevention – Opportunities to Improve Patient Care CME Credits: 0.5
Chemotherapy-induced nausea and vomiting (CINV) is a serious problem that can negatively impact a cancer patient’s quality of life and affect timely delivery of the most effective doses of chemotherapy treatment.
Faculty: Susan G. Urba, MD Expires: 10/8/2019

Considerations for Use of Immune Therapy to Treat Metastatic Colorectal Cancer CME Credits: 0.5
Colorectal cancer (CRC) is a leading cause of cancer-related deaths with poor 5-year survival rates for patients with metastatic disease. Patients with DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) are a distinct biomarker-defined population who may benefit less from conventional therapy compared with patients with MMR-proficient/microsatellite stable mCRC.
Faculty: Dung T. Le, MD Expires: 5/30/2020

Immunotherapy for the Treatment of Non-Small Cell Lung Cancer CME Credits: 1.0
Lung cancer is the leading cause of cancer-related mortality in the world, and approximately 85% of all lung cancer patients are diagnosed with non-small cell lung cancer (NSCLC).
Faculty: Jarushka Naidoo and Beatriz Wills Expires: 5/3/2020

Improving Outcomes in Stage III NSCLC: The Emerging Role of Immunotherapy in Curbing Disease Progression CME Credits: 0.5
Lung cancer is the worldwide leading cause of cancer-related mortality. The vast majority of these cases (about 85%) are characterized as nonsmall-cell lung cancer (NSCLC).
Faculty: Kristen Ashley Marrone, MD Expires: 9/29/2019

Integrating Immunotherapy into SCCHN Care: Implications for the Multidisciplinary Oncology Care Team CME Credits: 0.5
While the US Food and Drug Administration approval of cetuximab for treating patients with head and neck carcinomas may have introduced another agent to oncologists, these agents (that target oncogenes) have not yielded a prolonged clinical benefit for patients with head and neck cancer.
Faculty: Young Jun Kim, MD, PhD Expires: 6/15/2020

Novel Combination Therapies in HR+/HER2- Metastatic Breast Cancer: New Standards of Care? CME Credits: 1.0
Historically, the cornerstone of the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer has been endocrine therapy. Unfortunately, the development of endocrine resistance can limit the efficacy of this approach.
Faculty: Karen Lisa Smith, MD, MPH, and Maria Raquel Nunes, MD Expires: 7/30/2019

The Emerging Role of Immunotherapy in Treating Patients with Triple-Negative Breast Cancer CME Credits: 0.5
While the introduction of cetuximab for treating patients with head and neck carcinomas may have introduced another agent to oncologists, these agents (that target oncogenes) have not yielded a prolonged clinical benefit.
Faculty: Leisha A. Emens, MD, PhD Expires: 3/12/2019

The Role of the Oncology Nurse in Effective AE and Toxicity Management in Patients with Metastatic and Refractory Colorectal Cancer CME Credits: 0.5
Colorectal cancer (CRC) is the third leading cause of cancer-related deaths in the United States, expected to cause approximately 50 630 deaths in 2018.
Faculty: Cara Wilt, RN, MSN, CRNP Expires: 10/30/2019